Chagas Disease
A Clinical Approach
Samenvatting
Chagas disease is a potentially life threatening condition that was historically mainly endemic to Latin America. Over the last decade, however, the disease has spread to and is increasingly prevalent in other continents such as North America and Europe, with an estimated 7 million people infected worldwide. It is primarily transmitted by insect vectors that carry the parasite Trypanosoma cruzi, the disease agent. In areas where there is vector control and in non-endemic countries, it is mainly transmitted via congenital infection. Cardiac and gastrointestinal complications are common in untreated individuals.This book offers a comprehensive overview of Chagas disease, including its vectorial and congenital transmission, and molecular diagnosis, which is essential for screening, and developing and providing timely, effective anti-trypanosomal treatment. Written by experts working with infected patients on a daily basis, it discusses the pathogenesis of congenital, cardiac, gastrointestinal and oral Chagas disease, as well as its treatment and the pharmacological aspects of drug development in this area.
Chapter "Chagas Disease Treatment Efficacy Biomarkers: Myths and Realities" is available open access under a via link.springer.com.
Specificaties
Inhoudsopgave
<p>Chapter 1: Chagas disease: past, present and future</p>
<p>Hector Freilij</p>
<p>The agent</p>
<p>Chapter 2: Trypanosoma cruzi Journey from the Insect Vector to the Host Cell</p>
<p>Catalina D. Alba Soto and Stella M. González Cappa</p>
<p>Chapter 3: A panoramic view of the immune response to Trypanosoma cruzi infection</p>
<p>Gonzalo R. Acevedo, Magali C. Girard and Karina A. Gómez</p>
Epidemiology<p></p>
<p>Chapter 4: Epidemiology of Chagas Disease </p>
<p>Roberto Chuit, Roberto Meiss and Roberto Salvatella</p>
<p>Chapter 5: Chagas Disease in Europe</p>
<p>Julio Alonso-Padilla, María Jesús Pinazo and Joaquim Gascón</p>
<p>Chapter 6: Chagas Disease in the United States (USA)</p>
<p>Melissa S Nolan, Kyndall Dye-Braumuller and Eva Clark</p>
<p>Diagnosis</p>
<p>Chapter 7: Diagnosis of Chagas disease </p>
<p>Alejandro O Luquetti and Alejandro G. Schijman</p>
<p>Clinical aspects</p>
<p>Chapter 8: Acute vector-borne Chagas disease</p>
<p>Guillermo Moscatelli and Samanta Moroni</p>
<p>Chapter 9: Congenital Chagas Disease</p>
<p>Jaime Altcheh</p>
<p>Chapter 10: Chronic Trypanosoma cruzi Infection: </p>
<p>Decision Making in the Midst of Uncertainty</p>
<p>Juan Carlos Villar and Pablo Andrés Bermudez</p>
<p>Chapter 11: Orally-Transmitted Chagas Disease: a Neglected Foodborne Infection</p>
<p>Belkisyolé Alarcón de Noya and Oscar Noya González</p>
<p>Chapter 12: Gastrointestinal Chagas Disease</p>
<p> Ênio Chaves de Oliveira, Alexandre Barcelos Morais da Silveira and Alejandro O. Luquetti</p>
<p>Chapter 13: Chagas in immunosuppressed patients</p>
<p>Adelina R. Riarte, Marisa L. Fernandez, Claudia Salgueira and Javier Altclas</p>
<p>Treatment</p>
<p>Chapter 14: CLINICAL PHARMACOLOGY OF DRUGS FOR THE TREATMENT OF CHAGAS DISEASE</p>
<p>Facundo Garcia-Bournissen</p>
<p>Chapter 15: In vivo Drug Testing for Experimental Trypanosoma cruzi Infection</p>
<p>Julián Ernesto Nicolás Gulin </p>
<p>Chapter 16: Chagas Disease Treatment Efficacy Biomarkers: Myths and Realities</p>
Elizabeth Ruiz Lancheros, Eric Chatelain and Momar Ndao<p></p><p></p>
